Login
$IMUX
$7.23 -$0.29 (3.86%) Live

$IMUX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G
13 Nov 2026 8-K: Results of Operations and Financial Condition

– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 –

13 Nov 2026 10-Q
05 Nov 2026 8-K: Regulation FD Disclosure

On November 5, 2026, Immunic, Inc. (the “Company” or “Immunic”) is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar (the “PMS R&D Day”). The PMS R&D Day will take place on Thursday, November 5, 2026, fr...

02 Nov 2026 SCHEDULE 13G/A
01 Oct 2026 S-8
18 Sep 2026 Form 4: Nagel Robert Thorvald, Director

Granted 25,370 Stock Option

18 Sep 2026 Form 4: Bvf Partners L P/IL, Director and 9 others

Granted 25,370 Stock Option

11 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

On September 10, 2026, Dr. Duane Nash resigned as a member of the Board of Directors (the “Board”) of Immunic, Inc., a Delaware corporation (the “Company”). Dr. Nash’s resignation was not the result of any disagreement with the Company o...

09 Sep 2026 8-K: Regulation FD Disclosure

On September 9, 2026, Immunic, Inc. (the “Company” or “Immunic”) is hosting a Relapsing Multiple Sclerosis (RMS) Research and Development Day webinar (the “RMS R&D Day”). The RMS R&D Day will take place on Wednesday, September 9, 2026, f...

14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 S-8
11 Aug 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness –

11 Aug 2026 10-Q
10 Aug 2026 Form 4: Ridloff Elena, Director

Granted 50,740 Stock Option

10 Aug 2026 Form 3: Ridloff Elena, Director

No securities owned

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support